BACKGROUND: Breast cancer is one of the most common cancers in women in the world. Health-related quality of life (HRQL) at treatment endpoint in cancer clinical trials is widely considered to be increasingly important. The aim of this review was to provide a literature-based assessment of the validity, reliability and responsiveness of breast cancer-specific HRQL instruments in women breast cancer patients. MATERIALS AND METHODS: The databases consulted were Medline, PubMed, and Embase. The inclusion criteria required studies to: (1) involve use of HRQL measures; (2) cover women with breast cancer under standard treatment (surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy); (3) involve the validity, reliability, or responsiveness of HRQL; (4) deal with validation of breast cancer-specific HRQL instruments. RESULTS: A total of 16 studies were identified through the literature search that met the 4 inclusion criteria. Some seven instruments were assessed among these 16 studies: EORTC QLQ-BR23, FACT-B, FACT-ES, HFRDIS, LSQ- 32, QLICP-BR, and SLDS-BC. EORTC QLQ-BR23, FACT-B, LSQ-32, QLICP-BR, and SLDS-BC are more general breast cancer-specific HRQL instruments. FACT-EB is the endocrine subscale combined with FACT-B in order to measure the side effects and putative benefits of hormonal treatment administered in breast cancer patients. HFRDIS is the HRQL measure focusing on hot flash concerns. CONCLUSIONS: This paper provides an overall understanding on the currently available breast cancer-specific HRQL instruments in women breast cancer patients.
BACKGROUND:Breast cancer is one of the most common cancers in women in the world. Health-related quality of life (HRQL) at treatment endpoint in cancer clinical trials is widely considered to be increasingly important. The aim of this review was to provide a literature-based assessment of the validity, reliability and responsiveness of breast cancer-specific HRQL instruments in womenbreast cancerpatients. MATERIALS AND METHODS: The databases consulted were Medline, PubMed, and Embase. The inclusion criteria required studies to: (1) involve use of HRQL measures; (2) cover women with breast cancer under standard treatment (surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy); (3) involve the validity, reliability, or responsiveness of HRQL; (4) deal with validation of breast cancer-specific HRQL instruments. RESULTS: A total of 16 studies were identified through the literature search that met the 4 inclusion criteria. Some seven instruments were assessed among these 16 studies: EORTC QLQ-BR23, FACT-B, FACT-ES, HFRDIS, LSQ- 32, QLICP-BR, and SLDS-BC. EORTC QLQ-BR23, FACT-B, LSQ-32, QLICP-BR, and SLDS-BC are more general breast cancer-specific HRQL instruments. FACT-EB is the endocrine subscale combined with FACT-B in order to measure the side effects and putative benefits of hormonal treatment administered in breast cancerpatients. HFRDIS is the HRQL measure focusing on hot flash concerns. CONCLUSIONS: This paper provides an overall understanding on the currently available breast cancer-specific HRQL instruments in womenbreast cancerpatients.
Authors: Alejandro Álvarez-Bustos; Cristina G de Pedro; María Romero-Elías; Javier Ramos; Pablo Osorio; Blanca Cantos; Constanza Maximiano; Miriam Méndez; Carmen Fiuza-Luces; Marta Méndez-Otero; Silvia Martín; Héctor Cebolla; Ana Ruiz-Casado Journal: Support Care Cancer Date: 2021-04-28 Impact factor: 3.603
Authors: Diriba Alemayehu Gadisa; Esayas Tadesse Gebremariam; Getnet Yimer Ali Journal: Health Qual Life Outcomes Date: 2019-12-12 Impact factor: 3.186
Authors: Blanca Prieto-Callejero; Francisco Rivera; Javier Fagundo-Rivera; Adolfo Romero; Macarena Romero-Martín; Juan Gómez-Salgado; Carlos Ruiz-Frutos Journal: Medicine (Baltimore) Date: 2020-08-14 Impact factor: 1.817